Iovance Biotherapeutics, Inc. IOVA
11.00
0.20
1.85%
as of 25 Sep
- Market cap
- $4.9B
- P/E
- 0.0×
Follow IOVA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.76 | 5.14 | 3.70 | 3.15 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(30.78) | (20.38) | (18.56) | (10.04) | |
P/B ratio |
2.54 | 2.04 | 1.40 | 1.12 | |
Price to Tangible BV |
3.97 | 3.25 | 2.33 | 1.89 | |
EV/Sales |
4.85 | 4.05 | 2.58 | 1.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.97) | (4.27) | (2.25) | (1.52) | |
EV/FCF |
(5.32) | (3.79) | (2.02) | (1.39) | |
Quick Ratio |
3.74 | 3.05 | 2.74 | 2.92 | |
Current Ratio |
4.35 | 3.60 | 3.20 | 3.41 | |
Net Debt/EBITDA |
6.76 | 4.44 | 4.78 | 3.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.36 | 0.30 | 0.29 | 0.26 | |
Operating CF/Net income |
1.29 | 0.91 | 0.73 | 0.86 | |
Capex/Depreciation |
(0.69) | (0.63) | (0.82) | (1.11) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
59.26% | 87.48% | 82.06% | 111.44% | |
Selling, General and Administrative Expense of Revenue |
39.54% | 54.53% | 41.95% | 51.23% | |
Intangible Assets out of Total Assets |
0.29 | 0.29 | 0.31 | 0.32 | |
Share Based Compensation of Revenue |
11.81% | 15.78% | 13.62% | 17.64% | |
Graham Net Nets |
0.15 | 0.18 | 0.23 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.55%) | (27.07%) | (41.03%) | (55.30%) | |
Free Cash Flow Yield |
(15.83%) | (20.76%) | (34.47%) | (44.54%) | |
Revenue per Share |
0.22 | 0.17 | 0.24 | 0.19 | |
Operating CF per Share |
(0.14) | (0.17) | (0.15) | (0.22) | |
Capex per Share |
(0.01) | (0.02) | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.15) | (0.19) | (0.17) | (0.25) | |
Cash per Share |
0.66 | 0.75 | 0.83 | 0.83 | |
Shareholders Equity per Share |
1.64 | 1.72 | 1.95 | 1.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.64 | 1.72 | 1.95 | 1.93 | |
Free Cash Flow |
(66.28) | (78.68) | (61.88) | (89.55) | |
Working Capital |
357.41 | 337.08 | 304.33 | 303.31 | |
Capital Expenditures |
(5.44) | (6.61) | (9.32) | (10.84) | |
Net Current Asset Value |
284.77 | 262.59 | 228.10 | 226.43 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.09 | 0.11 | 0.16 | |
Net Profit Margin |
(47.64%) | (110.66%) | (82.87%) | (135.28%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
81.03 | 76.35 | 75.89 | 61.26 | |
Average Payables |
29.11 | 32.97 | 24.83 | 31.46 | |
Average Inventory |
52.71 | 61.96 | 51.60 | 45.14 | |
Average Assets |
911.48 | 946.20 | 911.80 | 948.03 | |
Average Common Equity |
717.26 | 744.81 | 704.49 | 737.87 |
Columns are period end dates